We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Single-Use Test Strip to Revolutionize Disease Diagnosis

By LabMedica International staff writers
Posted on 09 Feb 2026

Early detection is critical for diseases such as cancer, but many biological warning signals circulate in the blood at levels too low to be reliably detected. More...

MicroRNAs are among the most promising early biomarkers, yet their extremely low concentrations often place them beyond the reach of standard laboratory tests. This diagnostic gap limits early intervention and timely treatment decisions. A new single-use test strip now demonstrates that these elusive molecular signals can be detected quickly and sensitively without complex lab infrastructure.

Inspired by glucose test strips, the biosensor developed by researchers at La Trobe University (Victoria, Australia) uses an electrochemical readout to detect disease-associated microRNAs in blood plasma. The key innovation lies in integrating a specialized enzyme that dramatically amplifies subtle electrical changes generated when microRNAs bind to the sensor surface.

When a biological sample is added to the strip, the presence of a target microRNA alters the electrical signal produced by the sensor. The enzyme enhances this response, allowing the system to detect microRNAs at concentrations up to a trillion times lower than glucose levels. This sensitivity surpasses many existing molecular techniques and enables detection even when biomarkers are present in extremely small amounts.

The biosensor was validated using blood plasma samples, where it successfully detected microRNAs at concentrations up to 1,000 times lower than previously achievable with similar strip-based technologies. The results, published in Small, show that enzyme amplification enables robust and reproducible detection of microRNAs that are typically difficult to measure using standard PCR-based assays.

This technology opens the door to point-of-need diagnostics that do not rely on centralized laboratories or highly trained personnel. The researchers envision the test strip being incorporated into portable devices for routine disease screening, monitoring treatment response, and enabling earlier diagnosis of conditions such as cancer. Further development will focus on expanding the range of detectable microRNAs and translating the technology into clinical settings.

“It is exciting to be one step closer to disease diagnosis and monitoring that is truly point-of-need: affordable, convenient, accessible, and effective,” said Distinguished Professor Brian Abbey, Senior Researcher, La Trobe University, and co-developer of the biosensor.

Related Links:
La Trobe University


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.